Our Board

Stuart is a world-renowned biophysicist. A foreign associate of the French Academy of Science, his academic curriculum includes professorships at Cornell University (NY, USA), University of Geneva (Switzerland), ENS (Paris, France) and the Collège de France. Stuart also has start-up experience as co-founder of a publicly listed biotech company.

Philippe, a partner at Seventure Partners, is in charge of life siences investments for the Quadrivium I fund. He started his career as a Project Manager and Director of Business Development Europe in the Rhodia group and later founded a market and business intelligence company, CBDMT – Market & Business Intelligence, which he managed for 10 years prior to joining Seventure.

Arnaud is Investment Principal at M Ventures and based in Amsterdam. He received a PhD in immunology from the Pasteur Institute and a MSc in Finance from ESCP Europe. He started his career at KPMG as a Financial Auditor in the Healthcare business unit. He then worked at Seventure Partners as Senior Associate where he invested in Life Sciences companies.

Stéphane is involved in the development and management of core facility as a Chargé de mission to the President of the Sorbonne Université (Paris, France). In addition to this position, Stéphane teaches genomics at Sorbonne Université in the Laboratory of Computational and Quantitative Biology (LCQB), and heads the genomics facility at the École normale supérieure (Paris).

Jean-Pascal Viola is the senior vice president, head of the molecular diagnostics business area at QIAGEN, in addition to his role as leader of corporate business development and intellectual property and litigation. He joined Qiagen in 2005 and has held various roles in Singapore, the US, and Germany. He played a leading role in the acquisitions of Cellestis, Stat-Dx, NeuMoDx, and the assets of Forumlatrix related to digital PCR.

Frank is Senior Investment Manager at High-Tech Gründerfonds. He brings significant experience in biotechnology, as a scientist and founder of OncoMab GmbH, a spin-off of the University of Würzburg's Institute of Pathology. This expert in tumour-reactive antibodies focuses on the development of biologicals from the manufacturing phase to the clinical-trial stage.

Marc is Equity Portfolio Manager at Financière Arbevel since 2014. He graduated at HEC Business School and started his career at Bossard and Arthur D.Little, Organisation and Strategy Consulting Firms. Since more than 20 years, he developed his expertise in the biotechnologies field and held responsibilities as Executive Director and Entrepreneur at BioProtein, Alfact, Cellectis, CYTOO, Clevexel. Marc also served on the INSERM scientific committee between 2008 and 2016.

Anique is Investment Associate at M Ventures and based in Amsterdam. She obtained a PhD in biomedical sciences from the Radboud Institute of Molecular Life Sciences in the Netherlands. During her PhD, Anique studied mechanisms of vascular calcification and potential interventions in cellular and animal models. Anique obtained a Master’s degree at the VU University Amsterdam in biomedicine and fulfilled the extracurricular program Science Based Business at Leiden University.